BerGenBio: Funded to achieve multiple value inflection points
BerGenBio is making excellent progress towards achieving its ambitious goals. All six Phase II trials with bemcentinib (BGB324) are on track to report data in 2018, with results from the most of them expected at the ASCO meeting in June. The first efficacy data with bemcentinib in immuno-oncology settings should be reported there, from the three Phase II studies in combination with Merck’s pembrolizumab. BerGenBio continues to control its costs carefully and is funded to operate into FY19. Our valuation is maintained at NOK50.46/share.
BerGenBio is a clinical stage biopharmaceutical company focused on developing innovative drugs for aggressive, drug resistant cancers. Co.'s lead product, BGB324, is a selective, potent and orally available small molecule AXL inhibitor. It is in Phase II clinical development, as a single agent and in combination with marketed immuno-oncology drugs, in three cancer indications with potential: Acute myeloid leukaemia; Advanced non-small-cell lung cancer and Triple negative breast cancer. Co. is also developing a diversified pre-clinical pipeline of selective AXL inhibitors, including biologics and small molecules.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.